[ad_1] The U.S. FDA approval came for its Abbreviated New Drug Application (ANDA) for Travoprost Ophthalmic Solution. File. | Photo Credit: Reuters Drugmaker Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Travoprost Ophthalmic Solution USP, 0.004% (ionic buffered solution). The […]
Continue Reading
[ad_1] Drugmaker Granules India received U.S. FDA approval for manufacturing tablets for treating hypertension. Image for representational purpose only. | Photo Credit: AFP Drugmaker Granules India has received the U.S. Food and Drug Administration (USFDA) approval for a generic version of Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg that are indicated […]
Continue Reading
[ad_1] USFDA has classified Cipla’s Goa plant as ‘Official Action Indicated’. File. | Photo Credit: Special Arrangement Drug major Cipla on November 24 said the USFDA has classified its Goa plant as ‘Official Action Indicated’, impacting product approvals from the facility meant for the U.S. market. According to the U.S. Food and Drug Administration (USFDA) […]
Continue Reading
[ad_1] Eligible for 180 days shared exclusivity for Brivaracetam tablets. Eligible for 180 days shared exclusivity for Brivaracetam tablets. Drugmaker Zydus Lifesciences has received the United States Food and Drug Administration (USFDA) approval to market Brivaracetam tablets. An antiepileptic drug, the approved product is a generic of multinational pharma firm UCB’s Briviact. “U.S. subsidiary Zydus […]
Continue Reading
[ad_1] Pharma major Dr. Reddy’s Laboratories has entered into a licensing agreement to obtain rights to New Jersey-based Slayback Pharma’s Brimonidine Tartrate Ophthalmic Solution 0.025%. Slayback Pharma is the first to file an ANDA (abbreviated new drug application) for the private label equivalent for Lumify with the U.S. Food and Drug Administration (USFDA) under Paragraph […]
Continue Reading